ArticleFrontiers in oncology2022

Comparison of real-world data (RWD) analysis on efficacy and post-progression outcomes with pembrolizumab plus chemo vs chemo alone in metastatic non-squamous non-small cell lung cancer with PD-L1 < 50.

Ilaria Attili et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.